Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

393
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
393
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

268
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
268
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
Drug Regulation01:25

Drug Regulation

3.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.4K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

944
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
944

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune signatures underlying post-acute COVID-19 lung sequelae.

Science immunology·2021
Same author

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Blood cells, molecules & diseases·2017
Same author

Preoperative imaging should be performed prior to surgery in all cases of acquired nasolacrimal obstruction-Yes.

Eye (London, England)·2016
Same author

'Preoperative imaging should be performed for all cases of acquired nasolacrimal duct obstruction'-No.

Eye (London, England)·2016
Same author

Orphan drugs: expensive yet necessary.

QJM : monthly journal of the Association of Physicians·2015
Same author

On fragmenting, densely mineralised acellular protrusions into articular cartilage and their possible role in osteoarthritis.

Journal of anatomy·2014

Related Experiment Video

Updated: Apr 20, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K

Orphan drugs: expensive yet necessary.

H I Hyry1, J C P Roos1, T M Cox2

  • 1From the Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.

QJM : Monthly Journal of the Association of Physicians
|December 1, 2014
PubMed
Summary

Life-saving orphan treatments should be funded regardless of cost, based on John Rawls

Area of Science:

  • Health Economics
  • Bioethics
  • Public Health Policy

Background:

  • The high cost of orphan treatments presents a significant ethical and financial challenge to healthcare systems.
  • Patients with rare diseases often face treatment denial due to cost-effectiveness assessments and perceived strain on limited healthcare budgets.
  • Current approaches to funding orphan drugs are controversial, raising questions about equity and access to life-saving therapies.

Purpose of the Study:

  • To challenge the conventional use of cost-effectiveness assessments for life-saving orphan treatments.
  • To propose an ethical framework for funding orphan drugs based on John Rawls' theory of justice.
  • To establish guidelines for the appropriate application of cost-effectiveness analyses in healthcare resource allocation.

Main Methods:

More Related Videos

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.8K
Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

12.3K

Related Experiment Videos

Last Updated: Apr 20, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.8K
Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
07:55

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

Published on: August 4, 2011

12.3K
  • Philosophical analysis of John Rawls' theory of justice, specifically the concept of societal justice.
  • Development of three specific rules to limit the application of cost-effectiveness assessments.
  • Rebuttal of potential objections to the proposed ethical framework for orphan drug funding.

Main Results:

  • Cost-effectiveness assessments should not be used when the choice is between an only treatment and no treatment.
  • Efficiency assessments are inappropriate for prioritizing between different patients or patient groups.
  • Cost-effectiveness calculations may be applicable only when a patient has a choice between equally safe and effective treatments.

Conclusions:

  • Life-saving treatments, including orphan therapies, should be provided irrespective of their cost.
  • The distinction between individual patient needs and societal interests is artificial in the context of orphan drug funding.
  • Funding for orphan therapies is a critical public health issue, and treatment should not be withheld on economic grounds.